Eris Biotech develops first-in-class, orally administered small-molecule inhibitors designed to block cancer's immune evasion mechanisms. This approach reawakens the immune system to fight tumors without relying on specific protein targets. The resulting therapy offers a broad treatment option for patients by enhancing endogenous anti-tumor immunity.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Systemic cancer treatments often affect healthy tissues, leading to significant side effects and limiting the dosage that can be administered. The hypoxic conditions within the tumor microenvironment can also reduce the effectiveness of certain chemotherapeutic agents.
Solution
Eris Biotech is developing hypoxia-activated prodrugs designed to selectively target and treat cancerous tumors. These prodrugs remain inactive until they reach the low-oxygen environment characteristic of tumors, at which point they release their therapeutic payload directly at the site of the cancer. This targeted drug delivery mechanism aims to maximize efficacy while minimizing damage to healthy cells, potentially improving patient outcomes and quality of life during cancer treatment. By focusing on the unique characteristics of the tumor microenvironment, Eris Biotech's approach seeks to overcome limitations associated with traditional chemotherapy.
Target Audience
The primary target audience includes oncology researchers and pharmaceutical companies focused on developing more effective and less toxic cancer therapies, as well as cancer patients seeking treatments with reduced side effects.
Features
- Hypoxia-activated prodrug technology for targeted drug release
- Selective activation within the low-oxygen tumor microenvironment
- Minimized systemic toxicity due to localized drug delivery
- Potential for increased drug efficacy at the tumor site